摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-cyclobutyl-4-methyl-1H-pyrazol-5-amine | 1448854-98-5

中文名称
——
中文别名
——
英文名称
1-cyclobutyl-4-methyl-1H-pyrazol-5-amine
英文别名
1-Cyclobutyl-4-methyl-1H-pyrazol-5-amine;2-cyclobutyl-4-methylpyrazol-3-amine
1-cyclobutyl-4-methyl-1H-pyrazol-5-amine化学式
CAS
1448854-98-5
化学式
C8H13N3
mdl
——
分子量
151.211
InChiKey
VOEYTPZGUKTFRS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    309.2±22.0 °C(Predicted)
  • 密度:
    1.30±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    43.8
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    4-(4-chloro-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole1-cyclobutyl-4-methyl-1H-pyrazol-5-amine三氟乙酸potassium phosphatetris-(dibenzylideneacetone)dipalladium(0)R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下, 以 甲苯 为溶剂, 以25 mg的产率得到N-(1-cyclobutyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine trifluoroacetate
    参考文献:
    名称:
    9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
    摘要:
    本公开提供了代表为式I的替代的9H-嘧啶并[4,5-b]吲哚和5H-吡啶并[4,3-b]吲哚及相关类似物的药用可接受的盐、水合物和溶剂合物,其中R1a、A、B1、B2、G、X1、Y1、Y2和Y3如规范中所定义。本公开还涉及使用式I的化合物来治疗对BET溴结构域抑制敏感的状况或疾病。本公开的化合物特别适用于治疗癌症。
    公开号:
    US20150246923A1
  • 作为产物:
    描述:
    2-甲基-3-氧代丙腈1-环丁基肼盐酸盐乙醇 为溶剂, 以0.3 g的产率得到1-cyclobutyl-4-methyl-1H-pyrazol-5-amine
    参考文献:
    名称:
    9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
    摘要:
    本公开提供了代表为式I的替代的9H-嘧啶并[4,5-b]吲哚和5H-吡啶并[4,3-b]吲哚及相关类似物的药用可接受的盐、水合物和溶剂合物,其中R1a、A、B1、B2、G、X1、Y1、Y2和Y3如规范中所定义。本公开还涉及使用式I的化合物来治疗对BET溴结构域抑制敏感的状况或疾病。本公开的化合物特别适用于治疗癌症。
    公开号:
    US20150246923A1
点击查看最新优质反应信息

文献信息

  • 9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors
    申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    公开号:US10253044B2
    公开(公告)日:2019-04-09
    The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, A, B1, B2, G, X1, Y1, Y2, and Y3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.
    本公开提供了由式 I 表示的取代的 9H-嘧啶并[4,5-b]吲哚和 5H-嘧啶并[4,3-b]吲哚及相关类似物: 及其药学上可接受的盐、合物和溶液,其中 R1a、A、B1、B2、G、X1、Y1、Y2 和 Y3 如说明书中所定义。本公开还涉及使用式 I 的化合物治疗对抑制 BET 链有反应的病症或紊乱。本公开的化合物特别适用于治疗癌症。
  • 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS
    申请人:THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    公开号:US20170210761A1
    公开(公告)日:2017-07-27
    The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 1a , A, B 1 , B 2 , G, X 1 , Y 1 , Y 2 , and Y 3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.
  • US9580430B2
    申请人:——
    公开号:US9580430B2
    公开(公告)日:2017-02-28
  • [EN] 9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS<br/>[FR] 9H-PYRIMIDO[4,5-B]INDOLES ET LEURS ANALOGUES ASSOCIÉS COMME INHIBITEURS DE BROMODOMAINE BET
    申请人:UNIV MICHIGAN
    公开号:WO2015131005A1
    公开(公告)日:2015-09-03
    The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula (I) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, A, B1, B2, G, X1, Y1, Y2, and Y3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.
查看更多